Long-Acting PrEP With Cabotegravir Yields Substantial Benefit In Black People, But HIV Incidence Still Higher, Study Indicates

MedPage Today (2/22, Susman) reports, “Black individuals in the U.S. taking pre-exposure prophylaxis (PrEP) for HIV had substantial benefit with long-acting cabotegravir (Apretude), a substudy of the randomized...HPTN 083 trial showed, but they still face...